Interesting news, and confirms that the appetite by big pharma remains if the treatment regime appears to be a winner.
"AstraZeneca will also pay a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4 billion."
IFF CU6 is valued at US$2.4 billion = $14.00 / share = 5.2 times current price. My conclusion is that CU6 remains exceedingly cheap notwithstanding there's quite a way to go through the various FDA trials.
Research/Valuation, page-232
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.17 |
Change
-0.030(0.58%) |
Mkt cap ! $1.614B | |||
| Open | High | Low | Value | Volume |
| $5.24 | $5.46 | $5.09 | $3.028M | 578.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 5449 | $5.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.18 | 2736 | 10 |
View Market Depth
| Last trade - 13.49pm 04/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |